Shilpa Medicare
Shilpa Medicare Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 5 strong
The short version
Oncology API growth depends on molecule success and market commoditization; strong end-customer interest exists before investment. The company expects steady and robust growth across key verticals with improved operating leverage leading to higher margins and ROCE in coming years.
From Shilpa Medicare's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Oncology API growth depends on molecule success and market commoditization; strong end-customer interest exists before investment.
- Formulations have over 50% captive production, supporting stable growth.
- Biologics segment shows robust potential, growing at 42% YoY, expected to have significantly higher growth due to a smaller base and industry shift towards biologics.
- Biologics strategy is mixed: short-to-mid term focus on biosimilars and CDMO; long-term on strategic partnerships with high potential products.
- CDMO business is a key growth driver, with over 25 NCE programs in development and the potential for multiple commercial launches next year.
- API growth driven by specialty CDMO and capacity expansion, with selective investments ongoing.
- Formulation revenue doubled year-on-year, backed by complex FDA portfolio growth in the U.S. and other regions.
- Overall, the company foresees a robust and steady growth trajectory, with better profitability and returns on capital employed over time.
Profitability & Margins
See what Shilpa Medicare said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No significant new capital expenditure (capex) expected in Biologics or Albumin divisions as existing investments and capacities are underutilized and sufficient for growth in coming years.
- Additional capex continues in the API division and some new Formulation molecules where higher capacity utilization requires more investment.
- R&D investments are ongoing across divisions with respective budgets; focus is on advancing pipelines and adding new products, but detailed numbers are not disclosed.
- Strategic investments include selective stakes in smaller biotech companies to provide CDMO services; this is a confidential, unique strategy with no detailed public disclosure.
- Capacity utilization in Bangalore, Jadcherla, and Dharwad plants is monitored; segmental utilization details available on request.
- Overall approach prioritizes sweating existing assets while selectively investing in areas with growth potential.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shilpa Medicare said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Shilpa Medicare currently has more than 25 NCE (New Chemical Entity) programs in various development stages across the group.
- They have 3 late-stage NCE programs expected to enter the commercial phase next year (FY27).
- On the CDMO side, the company has over 20 customers actively engaged.
- For oncology APIs, investments are made only when there is an end-customer already interested, providing good visibility on orders.
- The Biologics division has strategic partnerships like Alveolus Bio and mAbTree Biologics for long-term prospects.
- The CDMO pipeline is robust, with many programs still in early stages, creating potential for future orderbook growth.
- No specific client- or product-wise orderbook details were disclosed for confidentiality reasons.
Shilpa Medicare — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹437 Cr, net profit ₹108 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shilpa Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Shilpa Medicare Q1 FY27 results?
Oncology API growth depends on molecule success and market commoditization; strong end-customer interest exists before investment. The company expects steady and robust growth across key verticals with improved operating leverage leading to higher margins and ROCE in coming years.
What is Shilpa Medicare share price analysis?
Shilpa Medicare currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 56.0 with a market cap of ₹15,939 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shilpa Medicare planning capital expenditure?
No significant new capital expenditure (capex) expected in Biologics or Albumin divisions as existing investments and capacities are underutilized and sufficient for growth in coming years.
Keep Shilpa Medicare on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.